BIO-SYNTHETIC ARCHITECTURE

Sector Programs

• IRTAL (Integrated RNA-Therapeutic Assembly Line) (RNA-Targeting Discovery & Manufacturing Platform )

  **SYSTEM CLASSIFICATION** Integrated High-Throughput RNA-Therapeutic Discovery, Validation, and Synthesis Platform. **PRIMARY MISSION** To establish a unified, continuous-flow architecture for discovering, validating, and manufacturing RNA-targeting therapeutics by closing the gap between bead-based avidity enrichment and true monovalent affinity measurement. **INDUSTRY CHALLENGE** Conventional DNA-encoded library (DEL) screens against RNA targets suffer from high hit-attrition rates because bead-based selections report multivalent avidity rather than true monovalent affinity. Furthermore, DNA tags create non-specific interference on RNA-binding proteins, while fragmented downstream synthesis creates severe manufacturing latency. **HIGH-LEVEL SOLUTIONS** • **Label-Free Monovalent Validation:** Deploys a grating-coupled surface plasmon resonance (GC-SPR) Bio-Disc utilizing 5'-amine RNA coupling and chiral circular dichroism (CD) drift rejection to measure true monovalent Kd values across multi-zone addressable arrays. • **Zero-Shear Acousto-Magnetic Sorting:** Focuses a colloidal DEL matrix to the hydrodynamic zero-shear mid-plane of a precision-dimensioned folded serpentine channel via a high-frequency ultrasonic standing wave, executing continuous binary separation under ultra-low tether tension. • **Photocleavable Colloidal DEL Matrix:** Integrates a large-scale combinatorial library synthesized on monodisperse sub-micron core-shell particles featuring targeted photocleavable linkers for tag-free monovalent re-assay. • **Anhydrous TSA Oligonucleotide Synthesis:** Combines industrial Dynamic Axial Compression (DAC) columns with a closed-loop Thermal Swing Adsorption (TSA) zeolite solvent drying skid to produce kilogram-scale pharmaceutical-grade oligonucleotides with high solvent recovery. **TARGET APPLICATIONS** • **Oncoprotein mRNA Modulation:** Target upstream mRNA 5' UTR internal ribosome entry sites and secondary structures in historically undruggable drivers such as MYC and KRAS. • **Pre-mRNA Splicing Correction:** Mask intronic splicing silencers and repeat-expansion hairpins in SMN2, ALS, and Huntington's Disease using targeted antisense oligonucleotides (ASOs). • **Viral Genome Targeting:** Deploy catalytic RIBOTAC chimeras and ASOs against conserved viral pseudoknots and frameshifting elements. **PROJECTED PERFORMANCE OBJECTIVES** • Discovery Capacity: High-density compound screening through a rapid continuous sorting run followed by label-free monovalent re-assay. • Kinetic Resolution: Real-time, label-free Kd quantification spanning a broad dynamic range. • Force Control: Peak tether tension clamped well below molecular rupture thresholds. • Manufacturing Yield: Kilogram-scale weekly output of high-purity modified RNA with high step-wise coupling efficiency and ultra-low moisture. **PARTNERSHIP & NDA-GATED TECHNICAL BRIEF** • **Development Status:** Master Technical Record and Engineering Audit Complete. • **Collaboration Request:** Seeking co-development, licensing, strategic investment, or clinical manufacturing partnerships. • **Notice:** Detailed serpentine channel dimensions, exact acoustic drive frequencies, Halbach magnetic field gradients, photocleavable linker stoichiometry, specific compound library volumes, and phosphoramidite coupling kinetics are strictly withheld and available only under NDA.

• APEX (Adaptive Persister Eradication Matrix) ()

  **SYSTEM CLASSIFICATION** Targeted Adaptive Persister Eradication Matrix and Stratified Biomarker Platform. **PRIMARY MISSION** To systematically eliminate minimal residual disease (MRD) and prevent polyclonal relapse in targeted cancer therapies by identifying and collapsing the YAP/TEAD transcriptomic survival scaffold in drug-tolerant persister cells. **INDUSTRY CHALLENGE** Standard targeted therapies initially induce significant tumor shrinkage, but fail to achieve cure because a subset of cells enters a non-mutational, drug-tolerant persister state. These persister cells survive initial treatment and eventually seed polyclonal relapse. Unselected combination regimens routinely fail due to cumulative toxicity penalties and an inability to distinguish mere pathway output from true survival dependency. **HIGH-LEVEL SOLUTIONS** • **Clonogenic Dependency Stratification:** Validates persister vulnerability using a localized TEAD target-gene panel directly tied to clonogenic frequency reduction via Extreme Limiting Dilution Analysis (ELDA), ensuring drug administration is gated on functional dependency rather than passive gene expression. • **Stratified Combination Dominance:** Implements a population-stratified mathematical dominance model that restricts combination dosing strictly to the biomarker-positive residual disease stratum, guaranteeing net therapeutic superiority even under real-world toxicity-driven dose reduction penalties. • **Multinomial Polyclonal Seeding Track:** Utilizes a conditional logit seeding model extended for polyclonal dynamics, tracking residual clone reactivation vectors from on-treatment biopsies to achieve high statistical power in small clinical cohorts without requiring massive prospective sample sizes. • **Dual-Node Transcriptomic Disruption:** Combines primary targeted agents with selective TEAD autopalmitoylation inhibitors during the minimal residual disease window, disrupting the YAP/TEAD nuclear interaction to trigger synthetic lethality in persister populations. **TARGET APPLICATIONS** • **EGFR-Mutant NSCLC Minimal Residual Disease:** Eradicating drug-tolerant persister cells following primary targeted treatment to delay or eliminate systemic disease progression. • **Extracranial Polyclonal Relapse Prevention:** Suppressing multi-clonal seeding vectors in advanced solid tumors presenting high residual YAP/TEAD transcriptomic scores. • **Companion Diagnostic Stratification:** Deploying residual tissue RNA/IHC companion panels to select patient populations capable of deriving net benefit from combination TEAD inhibition. **PROJECTED PERFORMANCE OBJECTIVES** • Dependency Verification: Direct correlation established between high residual TEAD transcriptomic scores and clonogenic frequency suppression in persister cell models following drug washout. • Cohort Statistical Efficiency: High statistical power achieved in small clinical trial cohorts by leveraging multinomial polyclonal seeding mechanics from paired on-treatment and relapse biopsies. • Stratified Utility Optimization: Positive net therapeutic benefit secured exclusively within the biomarker-selected cohort under real-world combination dose reductions. • Residual Disease Target Capture: High target-capture probabilities achieved by optimizing selection threshold parameters to raise the dependent cell fraction in the treated population. **PARTNERSHIP & NDA-GATED TECHNICAL BRIEF** • **Development Status:** Master Technical Record, Statistical Audit, and Preclinical Protocol Complete. • **Collaboration Request:** Seeking co-development, licensing, clinical trial biobank access, or strategic investment partnerships. • **Notice:** Detailed multinomial likelihood formulations, specific RNA/IHC scoring algorithms, ELDA protocol parameters, and clinical trial cohort stratification designs are strictly withheld and available only under NDA.